Literature DB >> 11019606

Role of sucralfate in gastrointestinal diseases.

M Candelli1, E Carloni, A Armuzzi, G Cammarota, V Ojetti, G Pignataro, A Santoliquido, R Pola, E Pola, G Gasbarrini, A Gasbarrini.   

Abstract

Sucralfate is a cytoprotective drug widely used in clinical practice to prevent or treat several gastrointestinal diseases such as gastro-esophageal reflux, gastritis, peptic ulcer, stress ulcer and dyspepsia. Sucralfate is a safe and well tolerated drug, as demonstrated by the quite complete lack of side effects and it is, for this reason, one of the most important therapeutic choices in the management of acid related diseases during pregnancy. Moreover, sucralfate has recently been shown to be useful in non-acid related gastrointestinal disease as well. In fact, sucralfate has also been administered topically in patients with radiation-induced mucosal procto-sigmoiditis or ulcerative colitis with surprising results. The drug is actually able to form a physical barrier between epithelium and damaging agents (-bile salts, drugs, refluxate...). Moreover, sucralfate increases the local levels of fibroblast growth factors and induces a rise in the mucosal concentration of prostaglandins which are considered important factors in mucosal healing. The aim of this paper is to describe the current and probably forthcoming uses of sucralfate in the field of gastrointestinal disorders. Moreover, we investigate the role of sucralfate as a reliable means to prevent the occurrence of reflux-like symptoms after Helicobacter pylori eradication and in the management of Helicobacter pylori negative patients affected by non-ulcer dyspepsia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11019606

Source DB:  PubMed          Journal:  Panminerva Med        ISSN: 0031-0808            Impact factor:   5.197


  3 in total

1.  The effectiveness of sucralfate against stricture formation in experimental corrosive esophageal burns.

Authors:  Z Günyüz Temir; Aytaç Karkiner; Irfan Karaca; Ragip Ortaç; Aykut Ozdamar
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

2.  Efficacy and Safety of AlbisD Compared With Omeprazole 20 mg in Patients With Non-erosive Reflux Disease: A Randomized, Open-label, Active-controlled, Pilot Study.

Authors:  Eun Jin Kim; Oh Young Lee; Kang Nyeong Lee; Sung Joon Lee; Jae-Young Jang; Jin Woong Cho; Tae-Oh Kim
Journal:  J Neurogastroenterol Motil       Date:  2019-07-01       Impact factor: 4.924

Review 3.  Treatment costs to prevent or treat upper gastrointestinal adverse events associated with NSAIDs.

Authors:  Elham Rahme; Alan N Barkun; Viviane Adam; Marc Bardou
Journal:  Drug Saf       Date:  2004       Impact factor: 5.228

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.